A detailed history of Beck Bode, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Beck Bode, LLC holds 1,815,524 shares of ETNB stock, worth $16.7 Million. This represents 2.53% of its overall portfolio holdings.

Number of Shares
1,815,524
Holding current value
$16.7 Million
% of portfolio
2.53%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$6.18 - $11.66 $11.2 Million - $21.2 Million
1,815,524 New
1,815,524 $13.2 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $427M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Beck Bode, LLC Portfolio

Follow Beck Bode, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beck Bode, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beck Bode, LLC with notifications on news.